Regency Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Regency Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$143K	Hold	29,500	–	–	0.06%	64
2026 Q1	$69K	Hold	29,500	–	–	0.03%	60
2025 Q4	$39.8K	Hold	29,500	–	–	0.02%	62
2025 Q3	$44.5K	Hold	29,500	–	–	0.02%	58
2025 Q2	$34.2K	Hold	29,500	–	–	0.02%	58
2025 Q1	$46.9K	Hold	29,500	–	–	0.03%	43
2024 Q4	$89.4K	Hold	29,500	–	–	0.05%	49
2024 Q3	$109K	Hold	29,500	–	–	0.06%	46
2024 Q2	$121K	Hold	29,500	–	–	0.08%	47
2024 Q1	$465K	Sell	29,500 -300	-1%	-$4.13K	0.3%	41
2023 Q4	$451K	Buy	29,800 +14,800	+99%	+$216K	0.3%	42
2023 Q3	$301K	Buy	+15,000	New	+$381K	0.26%	39

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Regency Capital Management's ZNTL Position: Q2 2026 in Review

Regency Capital Management held its Zentalis Pharmaceuticals (ZNTL) position steady in Q2 2026 at 29,500 shares worth $143K. The position accounts for 0.06% of the portfolio, ranked #64.

Regency Capital Management first reported a position in ZNTL in Q3 2023 and has held it in 12 quarters since. The position peaked at $465K in Q1 2024. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

Regency Capital Management held 29,500 shares of Zentalis Pharmaceuticals worth $143K as of Q2 2026.
Regency Capital Management left its Zentalis Pharmaceuticals share count unchanged in Q2 2026.
Zentalis Pharmaceuticals made up 0.06% of Regency Capital Management's portfolio in Q2 2026, its #64 holding.
Regency Capital Management first reported a position in Zentalis Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
Regency Capital Management's Zentalis Pharmaceuticals position peaked at $465K in Q1 2024.
114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Regency Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.